Some studies have shown that PD-1/PD-L1 blockade has unprecedented efficacy in B cell lymphomas and can be used as an alternative to the failure of conventional treatment regimens (23, 24). The gene discussed is CD274; the disease is B-cell non-Hodgkin lymphoma.